ALLSCHWIL/BASEL, SWITZERLAND - 05 February 2010 - Actelion Ltd (SIX: ATLN) announced today that Roland Haefeli, Vice Pesident, Investor Relations & Public Affairs and member of the Actelion executive committee, will present at the upcoming BIO CEO & Investor Conference on Monday, February 8, 2010 at 9:30 a.m. Eastern time / 3:30 p.m. local time at the Waldorf Astoria Hotel in New York City.
To access the live and subsequently archived webcast of the presentation, visit "Events" in the Investor Relations section of Actelion's Web site at http://www.actelion.com, Investors section. An archived replay will be available for 3 months beginning 24 hours after the live presentation.
###
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2, 200 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN).
For further information please contact:
Roland Haefeli
Vice President, Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 646 737 49 72
